Geropsychopharmacology: Enhancing Benefit, Reducing Risk

描述（由申请人提供）：65岁以上的专利占13 占美国人口的30%，但他们却获得了超过35%的收入。 处方药和不成比例地遭受不利的经验， 精神药物我们在适当的知识方面的关键差距 精神病患者的药物治疗， 缺乏接受过老年临床药理学培训的新研究人员。这 K24奖通过支持进一步的职业生涯来解决这一重要问题 在老年精神药理学方面建立研究者的发展， 他在以病人为导向的研究中指导初级研究人员。的 该候选人的研究计划的首要目标是确定 影响个体间药代动力学和药效学变量 治疗结果，以及专门解决信息的缺乏 针对老年患者的新型抗抑郁药和抗精神病药。的 在拟议的K24奖励期间，主要发展目标是 候选人，以提高其在群体药代动力学方面的专业知识， 混合效果建模这是建立在他的研究目前的优势之上的 计划，并代表了一个非常显着的增强，允许更多的 最佳利用来自临床试验的稀疏药物浓度数据。的 第二个发展目标是让候选人加深对以下方面的了解 基础和数量遗传学。发展活动将主要发生在 在候选人当前R 01“持续药物治疗”的背景下， 老年痴呆症的焦虑”。本研究的目的是提高 治疗严重受影响患者的痴呆非认知症状。 这个方案将测试高选择性5-羟色胺再摄取抑制剂 （SSRI）西酞普兰和非典型抗精神病药利培酮的差异 有效改善行为症状和/或精神病， 出院后继续药物治疗期间。 候选人还建议通过工作来提高他作为导师的技能。 与经验丰富的医学教育工作者密切合作。他将招募至少两名新的 每年通过三项部门培训赠款， 是密切相关的。受训者将是医学生、住院医师、博士后 研究员和初级教员。 将特别强调增加 招募代表性不足的少数民族。申请人将指导学员 分析现有数据以及设计和实施临床研究。 指导的成功将由学员在同行评审中的生产力来判断 出版物和职业发展奖和研究的竞争 经费

Description (provided by applicant): Patents older than age 65 represent 13 percent of the U.S. population, yet they receive more than 35 percent of all prescription drugs and disproportionately suffer adverse experiences from psychotropic medications. The critical gaps in our knowledge of appropriate pharmacotherapy for elders with psychiatric illness are exacerbated by the shortage of new investigators trained in geriatric clinical pharmacology. This K24 award addresses this important problem by supporting further career development for an established investigator in geriatric psychopharmacology and his mentoring of junior investigators in patient-oriented research. The overarching goal of this candidate's research program is to determine inter-individual pharmacokinetic and pharmacodynamic variables affecting treatment outcome as well as to specifically address the dearth of information regarding newer antidepressants and antipsychotics in elderly patients. The primary developmental goal during the proposed K24 award period is for the candidate to enhance his expertise in population pharmacokinetics using mixed-effects modeling. This builds on the current strengths of his research program, and represents a very significant enhancement by permitting more optimal utilization of sparse drug concentration data from clinical trials. The secondary developmental goal is for the candidate to deepen his knowledge of basic and quantitative genetics. Developmental activities will occur primarily in the context of the candidate's current R01 "Continuation Pharmacotherapy for Agitation in Dementia". The goal of this study is to improve the treatment of non-cognitive symptoms of dementia in severely affected patients. This protocol will test if the highly selective serotonin reuptake inhibitor (SSRI) citalopram and the atypical antipsychotic risperidone are differentially effective in ameliorating behavioral symptoms and/or psychosis particularly during continuing pharmacotherapy upon discharge from a hospital setting. The candidate also proposes to enhance his skills as a mentor by working closely with experienced medical educators. He will recruit at least two new trainees per year through three Departmental training grants with which he is closely associated. Trainees will be medical students, residents, post-doctoral fellows and junior faculty. Particular emphasis will be given to increasing recruitment of under-represented minorities. The applicant will mentor trainees in analyses of existing data as well as design and implementation of clinical studies. Success in mentoring will be judged by trainee's productivity in peer-reviewed publications and competition for career development awards and research funding.